Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
PDL To Restructure After Sale Failed
March 10, 2008
| A version of this story appeared in
Volume 86, Issue 10
PDL BioPharma has ended a strategic review in which it tried to sell itself and will instead remain an independent company focused on developing antibodies for cancer and immunologic diseases. During the review, the biotech firm sold assets worth more than $525 million. It will distribute much of this cash to shareholders. PDL cut 320 jobs through the asset sales and now says it will cut another 260 positions. The firm expects to end up with about 300 employees.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter